Page 71 - Read Online

Page 14 of 14 Diab et al. J Cancer Metastasis Treat 2022;8:42 https://dx.doi.org/10.20517/2394-4722.2022.60

83. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity.
Nat Commun 2015;6:5997. DOI PubMed
84. Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer.
Cancer Discov 2016;6:270-85. DOI PubMed PMC
85. Tempero M, Oh DY, Tabernero J, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of
patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol 2021;32:600-8. DOI PubMed
86. Philip PA. Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question? Ann Oncol 2021;32:582-3. DOI
PubMed
87. Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 2016;15:2719-
32. DOI PubMed PMC
88. Ma HS, Poudel B, Torres ER, et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of
nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res 2019;7:428-42. DOI PubMed PMC
89. Byrne KT, Betts CB, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor
microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res 2021;27:4574-86. DOI PubMed PMC
90. Yang J. Dendritic cells in pancreatic cancer immunotherapy: vaccines and combination immunotherapies. Pathol Res Pract
2019;215:152691. DOI PubMed
91. Yang J, Shangguan J, Eresen A, Li Y, Wang J, Zhang Z. Dendritic cells in pancreatic cancer immunotherapy: vaccines and
combination immunotherapies. Pathol Res Pract 2019;215:152691. DOI PubMed
92. Hirooka S. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Anticancer Res 2011;31:3827-34.
PubMed
93. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic
cancer who have undergone surgical resection. J Surg Res 2012;173:299-308. DOI PubMed
94. Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes
and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28:e26-31. DOI PubMed
95. Dallal RM, Christakos P, Lee K, Egawa S, Son YI, Lotze MT. Paucity of dendritic cells in pancreatic cancer. Surgery 2002;131:135-
8. DOI PubMed
96. Baylor college of medicine, N. Th-1 Dendritic cell immunotherapy plus standard chemotherapy for pancreatic adenocarcinoma
(DECIST). Available from: https://clinicaltrials.gov/ct2/show/NCT04157127 [Last accessed on 27 September 2022].
97. Katsuda M, Miyazawa M, Ojima T, et al. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of
dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer
refractory to standard chemotherapy. Trials 2019;20:242. DOI PubMed PMC
98. Nagai K, Adachi T, Harada H, Eguchi S, Sugiyama H, Miyazaki Y. Dendritic cell-based immunotherapy pulsed with wilms tumor 1
peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial.
Anticancer Res 2020;40:5765-76. DOI PubMed
99. Hoshikawa M, Aoki T, Matsushita H, et al. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic
cancer. Biochem Biophys Res Commun 2018;495:2058-65. DOI PubMed
100. Lim SA, Kim J, Jeon S, et al. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells
in pancreatic cancer patients. Front Immunol 2019;10:496. DOI PubMed PMC
101. Dickson I. Pancreatic cancer: γδ T cells support PDAC. Nat Rev Gastroenterol Hepatol 2016;13:560. DOI PubMed
102. Seifert AM, List J, Heiduk M, et al. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal
adenocarcinoma. J Cancer Res Clin Oncol 2020;146:3233-40. DOI PubMed PMC
103. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol
2018;18:671-88. DOI
104. Moral JA, Leung J, Rojas LA, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature
2020;579:130-5. DOI PubMed PMC